Illumina, Inc. Profile Avatar - Palmy Investing

Illumina, Inc.

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications i…
Medical - Diagnostics & Research
US, San Diego [HQ]
ILMN/Leadership and Strategy

Risk Factors

By Management
10-Q
  1. On June 24, 2024, we completed the separation of GRAIL into a separate, independent publicly traded company. As of September 6, 2024, all previously disclosed regulatory proceedings in the United States and European Union related to our acquisition of GRAIL (the Acquisition) have come to an end. Litigation, regulation, and other proceedings related to or resulting from the Acquisition have resulted in operational restrictions and increased costs and could result in similar additional future consequences or further result in loss of revenues.

  2. City of Roseville General Employees Retirement System, et al. v. deSouza, et al

  3. City of Omaha Police and Firefighters Retirement System v. deSouza, et al.

10 more risks
End of ILMN's Analysis
CIK: 1110803 CUSIP: 452327109 ISIN: US4523271090 LEI: - UEI: -
Secondary Listings